Live Biotherapeutic Products And Microbiome CDMO Market

Global Live Biotherapeutic Products And Microbiome CDMO Market Size, Share & Industry Trends Analysis Report By Application (C.difficile, Crohns Disease, IBS, Diabetes, and Others), By Regional Outlook and Forecast, 2023 - 2029

Report Id: KBV-15531 Publication Date: May-2023 Number of Pages: 128
Special Offering:
Industry Insights | Market Trends
Highest number of Tables | 24/7 Analyst Support
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Live Biotherapeutic Products And Microbiome CDMO Market, by Application
1.4.2 Global Live Biotherapeutic Products And Microbiome CDMO Market, by Geography
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Global Live Biotherapeutic Products And Microbiome CDMO Market by Application
3.1 Global C.difficile Market by Region
3.2 Global Crohns Disease Market by Region
3.3 Global IBS Market by Region
3.4 Global Diabetes Market by Region
3.5 Global Others Market by Region

Chapter 4. Global Live Biotherapeutic Products And Microbiome CDMO Market by Region
4.1 North America Live Biotherapeutic Products And Microbiome CDMO Market
4.1.1 North America Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.1.1.1 North America C.difficile Market by Country
4.1.1.2 North America Crohns Disease Market by Country
4.1.1.3 North America IBS Market by Country
4.1.1.4 North America Diabetes Market by Country
4.1.1.5 North America Others Market by Country
4.1.2 North America Live Biotherapeutic Products And Microbiome CDMO Market by Country
4.1.2.1 US Live Biotherapeutic Products And Microbiome CDMO Market
4.1.2.1.1 US Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.1.2.2 Canada Live Biotherapeutic Products And Microbiome CDMO Market
4.1.2.2.1 Canada Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.1.2.3 Mexico Live Biotherapeutic Products And Microbiome CDMO Market
4.1.2.3.1 Mexico Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.1.2.4 Rest of North America Live Biotherapeutic Products And Microbiome CDMO Market
4.1.2.4.1 Rest of North America Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.2 Europe Live Biotherapeutic Products And Microbiome CDMO Market
4.2.1 Europe Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.2.1.1 Europe C.difficile Market by Country
4.2.1.2 Europe Crohns Disease Market by Country
4.2.1.3 Europe IBS Market by Country
4.2.1.4 Europe Diabetes Market by Country
4.2.1.5 Europe Others Market by Country
4.2.2 Europe Live Biotherapeutic Products And Microbiome CDMO Market by Country
4.2.2.1 Germany Live Biotherapeutic Products And Microbiome CDMO Market
4.2.2.1.1 Germany Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.2.2.2 UK Live Biotherapeutic Products And Microbiome CDMO Market
4.2.2.2.1 UK Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.2.2.3 France Live Biotherapeutic Products And Microbiome CDMO Market
4.2.2.3.1 France Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.2.2.4 Russia Live Biotherapeutic Products And Microbiome CDMO Market
4.2.2.4.1 Russia Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.2.2.5 Spain Live Biotherapeutic Products And Microbiome CDMO Market
4.2.2.5.1 Spain Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.2.2.6 Italy Live Biotherapeutic Products And Microbiome CDMO Market
4.2.2.6.1 Italy Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.2.2.7 Rest of Europe Live Biotherapeutic Products And Microbiome CDMO Market
4.2.2.7.1 Rest of Europe Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.3 Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market
4.3.1 Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.3.1.1 Asia Pacific C.difficile Market by Country
4.3.1.2 Asia Pacific Crohns Disease Market by Country
4.3.1.3 Asia Pacific IBS Market by Country
4.3.1.4 Asia Pacific Diabetes Market by Country
4.3.1.5 Asia Pacific Others Market by Country
4.3.2 Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market by Country
4.3.2.1 China Live Biotherapeutic Products And Microbiome CDMO Market
4.3.2.1.1 China Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.3.2.2 Japan Live Biotherapeutic Products And Microbiome CDMO Market
4.3.2.2.1 Japan Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.3.2.3 India Live Biotherapeutic Products And Microbiome CDMO Market
4.3.2.3.1 India Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.3.2.4 South Korea Live Biotherapeutic Products And Microbiome CDMO Market
4.3.2.4.1 South Korea Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.3.2.5 Singapore Live Biotherapeutic Products And Microbiome CDMO Market
4.3.2.5.1 Singapore Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.3.2.6 Malaysia Live Biotherapeutic Products And Microbiome CDMO Market
4.3.2.6.1 Malaysia Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.3.2.7 Rest of Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market
4.3.2.7.1 Rest of Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.4 LAMEA Live Biotherapeutic Products And Microbiome CDMO Market
4.4.1 LAMEA Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.4.1.1 LAMEA C.difficile Market by Country
4.4.1.2 LAMEA Crohns Disease Market by Country
4.4.1.3 LAMEA IBS Market by Country
4.4.1.4 LAMEA Diabetes Market by Country
4.4.1.5 LAMEA Others Market by Country
4.4.2 LAMEA Live Biotherapeutic Products And Microbiome CDMO Market by Country
4.4.2.1 Brazil Live Biotherapeutic Products And Microbiome CDMO Market
4.4.2.1.1 Brazil Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.4.2.2 Argentina Live Biotherapeutic Products And Microbiome CDMO Market
4.4.2.2.1 Argentina Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.4.2.3 UAE Live Biotherapeutic Products And Microbiome CDMO Market
4.4.2.3.1 UAE Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.4.2.4 Saudi Arabia Live Biotherapeutic Products And Microbiome CDMO Market
4.4.2.4.1 Saudi Arabia Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.4.2.5 South Africa Live Biotherapeutic Products And Microbiome CDMO Market
4.4.2.5.1 South Africa Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.4.2.6 Nigeria Live Biotherapeutic Products And Microbiome CDMO Market
4.4.2.6.1 Nigeria Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.4.2.7 Rest of LAMEA Live Biotherapeutic Products And Microbiome CDMO Market
4.4.2.7.1 Rest of LAMEA Live Biotherapeutic Products And Microbiome CDMO Market by Application

Chapter 5. Company Profiles
5.1 Arranta Bio Holdings, LLC (Recipharm AB) (EQT AB)
5.1.1 Company Overview
5.1.2 Financial Analysis
5.1.3 Segmental and Regional Analysis
5.1.4 Recent strategies and developments:
5.1.4.1 Acquisition and Mergers:
5.1.4.2 Geographical Expansions:
5.2 Cerbios-Pharma SA
5.2.1 Company Overview
5.3 Biose Industrie
5.3.1 Company Overview
5.3.2 Recent strategies and developments:
5.3.2.1 Geographical Expansions:
5.4 List Biological Laboratories, Inc.
5.4.1 Company Overview
5.5 AcuraBio Pty Ltd (Ampersand Capital Partners)
5.5.1 Company Overview
5.6 Wacker Chemie AG (Dr. Alexander Wacker Familiengesellschaft mbH)
5.6.1 Company Overview
5.6.2 Financial Analysis
5.6.3 Segmental and Regional Analysis
5.6.4 Research & Development Expenses
5.7 Quay Pharmaceuticals Ltd (SGS S.A.)
5.7.1 Company Overview
5.7.2 Financial Analysis
5.7.3 Segmental Analysis
5.7.4 Recent strategies and developments:
5.7.4.1 Partnerships, Collaborations, and Agreements:
5.8 BiomX, Inc.
5.8.1 Company Overview
5.8.2 Research & Development Expenses
5.9 Lonza Group AG
5.9.1 Company Overview
5.9.2 Financial Analysis
5.9.3 Segmental and Regional Analysis
5.9.4 Research & Development Expenses
5.9.5 Recent strategies and developments:
5.9.5.1 Acquisition, Joint Ventures, and Mergers:
5.10. 4D Pharma Plc
5.10.1 Company Overview
5.10.2 Financial Analysis
5.10.3 Research & Development Expense
HAVE A QUESTION?

HAVE A QUESTION?

Call: +1(646) 600-5072

SPECIAL PRICING & DISCOUNTS


  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities

Unique Offerings Unique Offerings


  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Support with 10% customization free after sale

Trusted by over
5000+ clients

Our team of dedicated experts can provide you with attractive expansion opportunities for your business.

Client Logo